FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of March 2004
Commission File No. 000-19865
CEDARA SOFTWARE CORP.
(Registrant's name)
6509 Airport Road
Mississauga, Ontario, Canada L4V 1S7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40F.
Form 20-F X Form 40-F
------------ ------------
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):________
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):________
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes No X
------------- ------------
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-____________
Documents Included as Part of this Report
No. Document
1. Press Release dated March 8, 2004 - Cedara Agrees to $50 Million
Equity Financing on Bought Deal Basis
Document No. 1
[GRAPHIC OMITTED]
C E D A R A
News Release
FOR IMMEDIATE RELEASE:
Attention: Business/Financial Editors
Cedara Agrees to $50 Million Equity Financing
on a Bought Deal Basis
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES
March 8, 2004
TORONTO, CANADA - CEDARA SOFTWARE CORP. (TSX:CDE/OTCBB:CDSWF) announced today
that it has entered into an agreement with a syndicate of underwriters led by
Canaccord Capital Corporation under which the underwriters have agreed to
purchase 5,000,000 common shares at a price of Cdn.$10.00 per share
representing an aggregate amount of issue of Cdn.$50 million. Cedara has
granted the underwriters an over-allotment option to purchase up to an
additional 750,000 common shares, exercisable for a period of 30 days after
the closing date, expected on or about March 25, 2004. The offering is subject
to customary regulatory approvals. Cedara intends to use these proceeds to
repay bank indebtedness, for working capital purposes, and to finance future
strategic acquisitions.
The securities offered have not been and will not be registered under the
United States Securities Act of 1933, as amended (the U.S. Securities Act) or
any other securities laws and may not be offered or sold within the United
States or to U.S. Persons unless registered under the U.S. Securities Act and
applicable state securities laws, or an exemption from such registration is
available. This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities in the United States.
About Cedara Software:
Cedara Software Corp. is a leading independent provider of medical
technologies for many of the world's leading medical device and healthcare
information technology companies. Cedara software is deployed in thousands of
hospitals and clinics worldwide. Cedara's advanced medical imaging
technologies are used in all aspects of clinical workflow including the
operator consoles of numerous medical imaging devices; Picture Archiving and
Communications Systems (PACS); sophisticated clinical applications that
further analyze and manipulate images; and even the use of imaging in
minimally-invasive surgery. Cedara is unique in that it has expertise and
technologies that span all the major digital imaging modalities including
magnetic resonance imaging (MRI), computed tomography (CT), digital X-ray,
ultrasound, mammography, cardiology, nuclear medicine, angiography, positron
emission tomography (PET) and fluoroscopy.
Certain statements contained in this news release are forward-looking and are
based on current expectations that are subject to a number of uncertainties
and risks, and actual results may differ materially. These uncertainties and
risks include, but are not limited to: the management of the growth of the
Company, dependence on key personnel of the Company, competitive pressures
(including price competition), changes in market activity, risks associated
with international operations, the development of new products and services,
the enhancement of existing products and services, the introduction of
competing products having technological and/or other advantages, the
dependence on key customers, regulatory changes to the health care industry,
seasonality, economic and political conditions and adequate protection of the
proprietary interests of the Company. Further information about these risks
and uncertainties can be found in the continuous disclosure documents filed
from time to time by Cedara with the securities regulatory authorities, which
documents are available at http://www.sedar.com/.
For investor-related inquiries, contact:
Fraser Sinclair, Chief Financial Officer and Corporate Secretary
(905) 672 2100 ext. 2405
Email: fraser.sinclair@cedara.com
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: March 9, 2004
CEDARA SOFTWARE CORP.
By: /s/ Fraser Sinclair
--------------------------
Fraser Sinclair
Chief Financial Officer